PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim. Based on the RE-LY study to evaluate the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings f...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
श्रृंखला:Racionalʹnaâ Farmakoterapiâ v Kardiologii
विषय:
dabigatran etexelate
warfarin
vitamin k antagonists
atrial fibrillation
pharmacoecomomics
clinic-economic evaluation
cost-effectiveness
markov modeling
ऑनलाइन पहुंच:https://www.rpcardio.com/jour/article/view/397
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन